Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT01846793
- Locations
- ๐บ๐ธ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Dallas, Texas, United States
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 141
- Registration Number
- NCT01620515
- Locations
- ๐บ๐ธ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Salt Lake City, Utah, United States
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 192
- Registration Number
- NCT01438775
- Locations
- ๐บ๐ธ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Houston, Texas, United States
๐บ๐ธFor information concerning this clinical site, please contact Nymox at 800-936-9669, San Antonio, Texas, United States
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00945490
- Locations
- ๐บ๐ธ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Richmond, Virginia, United States
๐บ๐ธFor information concerning this clinical site, please contact Nymox at 800-936-9669, Grand Rapids, Michigan, United States
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00918983
- Locations
- ๐บ๐ธ
For information concerning this clinical site, please contact Nymox at 800-936-9669, Bala Cynwyd, Pennsylvania, United States
๐บ๐ธFor information concerning this clinical site, please contact Nymox at 800-936-9669., Salt Lake City, Utah, United States
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 85
- Registration Number
- NCT00759135
- Locations
- ๐บ๐ธ
Nymox Investigational Site, San Antonio, Texas, United States